Insys Therapeutics treatment of Dravet syndrome granted orphan status Insys Therapeutics' cannabidiol was designated for orphan designation as a treatment of Dravet syndrome, according to a post to the FDA's website. Reference Link
Insys Therapeutics receives FDA orphan drug designation for LEP-ETU Insys Therapeutics announced that the FDA has granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use, or LEP-ETU, candidate for the treatment of gastric cancer. LEP-ETU is an improved formulation of paclitaxel, a widely used chemotherapeutic agent. Insys acquired LEP-ETU during its merger in 2010 with NeoPharm.